View details of this raise on Seedstage

Santa Rosa, CA

Developing a medical device to target and remove Galectin-3, addressing sepsis progression.

• Innovative Medical Device: XGAL-3 is designed to remove Galectin-3 from the bloodstream, targeting the root cause of sepsis.
• FDA Breakthrough Designation: The device has received FDA Breakthrough Device Designation, facilitating an expedited review process.
• Extensive Patent Portfolio: Eliaz Therapeutics holds over 60 patents across 34 countries, protecting its technology.
• Significant Funding: The company has raised over $8 million to support its development and clinical trial efforts.
• Strategic Collaborations: Collaborations with leading research institutes enhance the development and potential impact of XGAL-3.

Eliaz Therapeutics has developed XGAL-3, a medical device designed to remove the Galectin-3 protein from the bloodstream, aiming to halt the progression of sepsis, a leading cause of death globally. The company has received FDA Breakthrough Device Designation, which facilitates an expedited review process for technologies addressing urgent medical needs. With over $8 million in funding and 60 patents across 34 countries, Eliaz Therapeutics is advancing towards clinical trials.

The funding raised will be used to accelerate the clinical development of XGAL-3, build operational infrastructure, and prepare for potential commercialization. The device is designed to integrate with existing hospital apheresis machines, offering a targeted approach to sepsis treatment by rapidly removing Galectin-3 from the blood. This approach aims to address the underlying causes of sepsis rather than just managing symptoms, potentially providing a significant advancement in critical care treatment options.

Company Info

Eliaz Therapeutics is developing XGAL-3, a device to remove Galectin-3 from the blood, aiming to treat sepsis effectively.

Eliaz Therapeutics has developed XGAL-3, a medical device aimed at removing the Galectin-3 protein from the bloodstream to address sepsis, a leading cause of death worldwide. The device functions similarly to targeted dialysis, using specialized antibodies to eliminate Galectin-3, thereby aiming to halt the progression of sepsis. XGAL-3 is designed to integrate with existing hospital apheresis machines, making it a potentially seamless addition to critical care settings.

Beyond sepsis, Galectin-3 is implicated in various severe conditions, including chronic kidney disease and cancer. Eliaz Therapeutics holds over 60 patents across 34 countries, and the device has received FDA Breakthrough Device Designation, indicating its potential to address urgent medical needs. The company is advancing towards clinical trials, supported by strategic collaborations with leading research institutions and a robust intellectual property portfolio.